New drug plus chemoradiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (Becotatug Vedotin) combined with standard chemotherapy and radiation for locally advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with esophageal squamous cell carcinoma (a type of esophageal cancer) that is stage cT2-T4a or higher but not spread beyond nearby lymph nodes.
- You cannot have received any prior treatment for this cancer.
- You must be in good enough health to carry out daily activities (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver) must be within acceptable ranges.
- You cannot have had any other cancer in the last 5 years (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for advanced esophageal squamous cell carcinoma that has stopped responding to prior treatment. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.